CymaBay Therapeutics

157 articles about CymaBay Therapeutics

• CymaBay Therapeutics Announces Presentations During The Digital International Liver Congress™ 2020A featured presentation will highlight final results from a 1-year, open-label Phase 2 study of seladelpar in primary biliary cholangitis (PBC)

  8/20/2020

  CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases, today announced that two seladelpar presentations will be delivered during the Digital International Liver Congress™ 2020 of the European Association for the Study of Liver (EASL) which will be held online August 27 th – 29 th . The presentation titled “D

• CymaBay Reports Second Quarter 2020 Financial Results and Provides Corporate Update

  8/10/2020

  CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, announced corporate updates and financial results for the second quarter and six months ended June 30, 2020.

• 

  Clinical Catch-Up: August 3-7

  8/10/2020

  It was a moderately busy week for clinical trial news, with some particularly interesting announcements related COVID-19 vaccine trials. Here’s a look.
• 

  CymaBay Therapeutics' PBC Treatment Hits the Mark in Phase III Study

  8/3/2020

  Shares of CymaBay Therapeutics soared after the company announced its experimental primary biliary cholangitis (PBC) treatment seladelpar hit the mark in a Phase III study that sets up potential regulatory approval for this indication.

• CymaBay Therapeutics to Report Second Quarter 2020 Financial Results on Monday, August 10, 2020

  8/3/2020

  CymaBay Therapeutics, Inc. announced that it will host a conference call and live audio webcast on Monday, August 10, 2020 at 4:30 p.m. Eastern Time to discuss financial results for the second quarter and six months ended June 30, 2020 and to provide a business update.

• CymaBay Announces Positive Topline Results from ENHANCE for Seladelpar in Patients with Primary Biliary Cholangitis

  8/3/2020

  CymaBay Therapeutics, Inc. announced positive topline results from ENHANCE, a placebo-controlled, randomized, Phase 3 study evaluating the safety and efficacy of seladelpar for the treatment of primary biliary cholangitis.

• 

  Clinical Catch-Up: July 20-24

  7/27/2020

  It was a busy week for clinical trial news, with some very important early-stage trial data for various COVID-19 vaccines. Here’s a look.

• FDA Lifts All Clinical Holds on Seladelpar

  7/23/2020

  Clinical hold lifted on seladelpar INDs in NASH, PBC and PSC  Re-initiating clinical development focusing first on Phase 3 for PBC

• CymaBay Therapeutics Presents Data at Digestive Disease Week 2020 Online Education

  6/19/2020

  Data from previously completed open-label phase 2 study supports potential for seladelpar to improve pruritus (itching) in patients with PBC Improvements in other quality-of-life parameters also observed NEWARK, Calif., June 19, 2020 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases, today announced new data from a previously compl

• Notice of Change of Location of Annual Meeting of Stockholders to be Held on June 23, 2020CymaBay Therapeutics, Inc. Announces Change to Virtual Format for 2020 Annual Meeting of Stockholders

  6/5/2020

  CymaBay Therapeutics, Inc. (Nasdaq: CBAY),  today announced that, due to public health and safety concerns related to the COVID-19 global pandemic, recommendations and orders from federal, state and local authorities, and to support the health and well-being of its stockholders, employees and others,

• CymaBay Reports First Quarter 2020 Financial Results and Provides Corporate Update

  5/11/2020

  Independent expert panel unanimously concludes there is no clinical, biochemical or histological evidence of seladelpar-induced liver injury in the Phase 2b NASH study

• CymaBay Therapeutics to Report First Quarter 2020 Financial Results on Monday, May 11

  5/4/2020

  CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live audio webcast on Monday, May 11, 2020 at 4:30 p.m.

• CymaBay Therapeutics Comments on Engine Capital Director Nominations

  3/13/2020

  CymaBay Therapeutics, Inc. confirmed that Engine Capital Management has nominated three candidates to stand for election to the Company’s Board of Directors at the 2020 Annual Meeting.

• CymaBay Reports Fourth Quarter and Fiscal Year End 2019 Financial Results and Provides Corporate Update

  3/12/2020

  In parallel, board and management evaluating all potential strategic alternatives to maximize shareholder value and implementing cost containment efforts

• CymaBay Therapeutics to Report Fourth Quarter and Full Year 2019 Financial Results on Thursday, March 12

  3/5/2020

  CymaBay Therapeutics, Inc. announced that it will host a conference call and live audio webcast on Thursday, March 12, 2020 at 4:30 p.m. Eastern Time to discuss financial results for the fourth quarter and year ended December 31, 2019 and to provide a business update.

• CymaBay Publishes Shareholder Letter

  1/29/2020

  CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced the publication of a Letter to Shareholders.

• 

  Clinical Catch-Up: November 25-29

  12/2/2019

  Even with a shortened week due to the U.S. Thanksgiving holiday, there was plenty of clinical trial news and updates. Here’s a look.

• CymaBay Therapeutics Halts Clinical Development of Seladelpar

  11/25/2019

  CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, announced that the company was terminating its Phase 2b study of seladelpar in subjects with non-alcoholic steatohepatitis and its recently initiated Phase 2 study of seladelpar in subjects with primary sclerosing cholangitis.

• CymaBay Therapeutics to Present at Upcoming Investor Conferences

  11/14/2019

  CymaBay Therapeutics, Inc. announced that management will participate in two investor conferences including the Stifel 2019 Healthcare Conference taking place November 19-20, 2019 in New York City and the Evercore ISI 2nd Annual HEALTHCONx Conference in Boston, MA – December 3-5, 2019.

• 

  Clinical Catch-Up: November 4-8

  11/11/2019

  It was a busy week for clinical trial updates for the first week of November. Here’s a look.